As the founder of the Chinese genetics industry, and in line with the vision of “Trans-omics For a Better Life”, BGI Genomics has built a network of services that now cover more than one hundred countries worldwide and all of the provinces, municipalities, autonomous regions, and special administrative regions of China.
Through nearly 20 years of talent aggregation, research, and industry development, BGI has become one of the few comprehensive technology companies that are dedicated to the whole industry chain and all applications in the industry.
Relying on a technologically advanced, comprehensively equipped, and size-leading multi-omics platforms, BGI Genomics has become one of the few complete solution technology service providers and precision medicine operators.
The Company primarily provides genomic testing and research services for medical organizations, research institutions, enterprises and public institutions through genetic testing, mass spectrometry testing, bioinformatic analysis, and other means. To promote life science studies and the applications of the big data about life and improve global health, and based on the applications of the research results in the genetic field and precision testing technology in health, BGI Genomics strives to accelerate technological innovation, reduce birth defects, improve cancer prevention and control, prevent major diseases from causing harm to human beings, precisely cure infections, and promote the development of precision medicine.
Stock Information
Name：BGI Genomics Co.,Ltd.
CSRC Sector：Research & Development
CSRC Subsector：Professional Technical Service
Market：Shenzhen Stock Exchange (SZSE) ChiNext market
Listing date：2017-07-14
Financial Information
2019 Annual Report & BGI Genomics COVID-19 Pandemic Response Summary
Investor’s Exchange
Address: 7-14/F, Building 7, BGI Comprehensive Park, 21 Hong'an 3rd Street, Yantian District, Shenzhen, China
Email Address: ir@bgi.com
Phone: 0755-36307065